AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3299116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3299116 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 14
Study 31388720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-PET
Number of subjects: 71
Study 31388720 — intervention group
Group type: COMPARATOR
Intervention: CSF (Aβ42, tau, and phospho-tau)
Number of subjects: 71
Study 30374630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support for low-risk patients (18-month mortality risk ≤ 0.16)
Number of subjects: 1023
Study 30374630 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic support for intermediate- to high-risk patients (18-month mortality risk > 0.16)
Number of subjects: 1023
Study 30374630 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 1023
Study 30374630 — intervention group
Group type: COMPARATOR
Intervention: Basic support
Number of subjects: 1023
Study 28554913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolisation of abnormal knee neovasculature
Number of subjects: 58
Study 28554913 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 58
Study 26494450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (BH4, a nitric oxide synthase cofactor; 10 mg/kg)
Number of subjects: 11
Study 26494450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 22887834 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h per week of Nordic walking with poles for a 4-month period
Number of subjects: 213
Study 21302035 — intervention group
Group type: EXPERIMENTAL
Intervention: HTUPA 10 mg
Number of subjects: 32
Study 21302035 — intervention group
Group type: EXPERIMENTAL
Intervention: HTUPA 20 mg
Number of subjects: 32
Study 21302035 — intervention group
Group type: EXPERIMENTAL
Intervention: HTUPA 30 mg
Number of subjects: 32
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: p,p'-DDE
Number of subjects: 953
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-HCH
Number of subjects: 953
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: HCB
Number of subjects: 953
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: p,p'-DDT
Number of subjects: 953
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: OCPs levels
Number of subjects: 953
Study 19586652 — intervention group
Group type: EXPERIMENTAL
Intervention: p,p'-DDE and beta-HCB
Number of subjects: 953
Study 16483898 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 0
Study 15335019 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex dietary therapy including soy isoflavones and selenium
Number of subjects: 0
Study 10930895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin for 5 days, followed by subcutaneous heparin for 5 weeks (n=8)
Number of subjects: 20
Study 10930895 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous hydrocortisone for 5 days followed by oral prednisolone 40 mg daily, reducing by 5 mg per day each week (n=12)
Number of subjects: 20
Study 9780100 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive daunorubicin perfusion during standardized surgery
Number of subjects: 286
Study 9780100 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 286
Study 7530621 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insulin Therapy (CIT; n = 12)
Number of subjects: 36
Study 7530621 — intervention group
Group type: COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion (CSII; n = 12)
Number of subjects: 36
Study 7530621 — intervention group
Group type: COMPARATOR
Intervention: Intraportal Insulin Infusion (IPII; n = 12)
Number of subjects: 36
Study 7530621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (CSII)
Number of subjects: 36
Study 7530621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IPII)
Number of subjects: 36
Study 7530621 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 36
Study 3280505 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited individual psychotherapy
Number of subjects: 98
Study 3280505 — intervention group
Group type: COMPARATOR
Intervention: Time-limited group psychotherapy
Number of subjects: 98
Study 29633812 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% at 8 mL/h (Control)
Number of subjects: 64
Study 29633812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.4% at 4 mL/h
Number of subjects: 64
Study 28692468 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal pancreatectomy with intraperitoneal drainage
Number of subjects: 344
Study 28692468 — intervention group
Group type: COMPARATOR
Intervention: Distal pancreatectomy without intraperitoneal drainage
Number of subjects: 344
Study 25287553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (10-14 sessions: 6-10 during pregnancy and 4-8 after delivery)
Number of subjects: 300
Study 25287553 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 300
Study 25287553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 300
Study 24295530 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 × 30-minute training sessions using a joystick operated wheelchair simulation
Number of subjects: 28
Study 24295530 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no task)
Number of subjects: 28
Study 21569570 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional and multidimensional intervention including early geriatric assessment, early family support, case manager involvement, and planning with elderly and relatives.
Number of subjects: 100
Study 21569570 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 100
Study 18245904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 60
Study 18245904 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS)
Number of subjects: 60
Study 18245904 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement (AD)
Number of subjects: 60
Study 18245904 — intervention group
Group type: EXPERIMENTAL
Intervention: GS+AD
Number of subjects: 60
Study 18245904 — intervention group
Group type: COMPARATOR
Intervention: HA'
Number of subjects: 60
Study 18245904 — intervention group
Group type: COMPARATOR
Intervention: GS+HA'
Number of subjects: 60
Study 16436164 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint teleconferenced consultations with the patient, patient's general practitioner (GP), and a hospital specialist connected via ISDN2 link and video-conferencing software.
Number of subjects: 28
Study 12765983 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaison cardiac troponin I assay
Number of subjects: 0
Study 12765983 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (dalteparin) or an invasive strategy
Number of subjects: 0
Study 12765983 — intervention group
Group type: COMPARATOR
Intervention: AccuTnI assay
Number of subjects: 0
Study 14555594 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 microg once-daily
Number of subjects: 6
Study 14555594 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 or 200 microg once-daily
Number of subjects: 6
Study 14555594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) twice-daily (100, 200, or 500 microg)
Number of subjects: 6
Study 14555594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11059181 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood specimens obtained by finger prick stored on filter paper disks
Number of subjects: 0
Study 11059181 — intervention group
Group type: COMPARATOR
Intervention: Venous blood specimens
Number of subjects: 0
Study 11059181 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum specimens stored for 2 months
Number of subjects: 0
Study 8636587 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 81
Study 8636587 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 81
Study 8636587 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Bendrofluazide (combined analysis of quartiles)
Number of subjects: 81
Study 1352011 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (60 ml chlorhexidine diacetate 2 g/l)
Number of subjects: 4483
Study 1352011 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 4483
Study 6535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 72
Study 6535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 72
Study 6535067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3330126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-hormonotherapy (IMT)
Number of subjects: 43
Study 3330126 — intervention group
Group type: COMPARATOR
Intervention: Hormonotherapy (HT)
Number of subjects: 43
Study 31259585 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement status (Retired)
Number of subjects: 21000
Study 31259585 — intervention group
Group type: COMPARATOR
Intervention: Working status (Working older adults)
Number of subjects: 21000
Study 31259585 — intervention group
Group type: EXPERIMENTAL
Intervention: Time use redistribution
Number of subjects: 21000
Study 31028503 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 0
Study 31028503 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 0
Study 31028503 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical group (MgSO4)
Number of subjects: 0
Study 31028503 — intervention group
Group type: COMPARATOR
Intervention: Critical group (Routine treatment)
Number of subjects: 0
Study 28376726 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention (group teaching or printed material)
Number of subjects: 455
Study 26265641 — intervention group
Group type: EXPERIMENTAL
Intervention: Three intravitreal injections of bevacizumab (IVB) at monthly intervals.
Number of subjects: 44
Study 26265641 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) removal.
Number of subjects: 44
Study 23117286 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program
Number of subjects: 262
Study 23117286 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 262
Study 22117981 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic palonosetron 0.075 mg, intravenously before induction of inhalation anaesthesia
Number of subjects: 50
Study 22117981 — intervention group
Group type: COMPARATOR
Intervention: TIVA using propofol (target blood concentration 2.5‐6.0 μg/ml) and remifentanil (target blood concentration 2.5‐6.0 ng/ml)
Number of subjects: 50
Study 19497624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen replacement therapy (ERT)
Number of subjects: 2
Study 19497624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (ERT)
Number of subjects: 2
Study 17279193 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller multivitamin tablets
Number of subjects: 0
Study 17279193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin tablets with less iron content
Number of subjects: 0
Study 17279193 — intervention group
Group type: COMPARATOR
Intervention: Standard multivitamin tablets (larger size, higher iron content)
Number of subjects: 0
Study 15588135 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum dopamine‐beta‐hydroxylase (DBH) activity in healthy subjects
Number of subjects: 250
Study 15588135 — intervention group
Group type: EXPERIMENTAL
Intervention: DBH activity in Wistar rats
Number of subjects: 250
Study 15588135 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological parameters in healthy adolescents
Number of subjects: 250
Study 11768897 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed intravascular thrombolysis using thrombus-dissolving enzymes (streptokinase, urokinase, tissue plasminogen activators)
Number of subjects: 0
Study 11768897 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thrombolysis in late and longer lasting occlusions (>14 days)
Number of subjects: 0
Study 9228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sepsis (n=49)
Number of subjects: 49
Study 9228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died (n=14)
Number of subjects: 49
Study 9228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who recovered (n=35)
Number of subjects: 49
Study 9228516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sepsis (n=43)
Number of subjects: 49
Study 9228516 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 49
Study 7969611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care treatment for more than 30 days
Number of subjects: 223
Study 3675911 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypromellose
Number of subjects: 88
Study 3675911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 88
Study 3675911 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 88
Study 31612537 — intervention group
Group type: EXPERIMENTAL
Intervention: Betanodavirus (one RGNNV genotype and two BFNNV genotypes)
Number of subjects: 0
Study 28860166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg ×3/day)
Number of subjects: 26
Study 28860166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 25769195 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored aerobic exercise (40 minutes, 2 days/week, 3 months)
Number of subjects: 100
Study 24030249 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Report of Children's Abilities-Revised (PARCA-R)
Number of subjects: 204
Study 20621454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine supplementation
Number of subjects: 931
Study 20621454 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine long-acting injection (olanzapine-LAI)
Number of subjects: 931
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/Calibra resin cement with Self‐cure and Self‐cure (SC&SC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/Calibra resin cement with Self‐cure and Dual‐cure (SC&DC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/Calibra resin cement with Dual‐cure and Dual‐cure (DC&DC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/FluoroCore 2 with Self‐cure and Self‐cure (SC&SC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/FluoroCore 2 with Self‐cure and Dual‐cure (SC&DC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: XP BOND‐Dual Cure/FluoroCore 2 with Dual‐cure and Dual‐cure (DC&DC)
Number of subjects: 42
Study 18652271 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal region
Number of subjects: 42
Study 16774958 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin enhanced feeder vessel therapy with varying light doses (50 J/cm2, 100 J/cm2, 125 J/cm2, 150 J/cm2)
Number of subjects: 9
Study 12932084 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bright light (> 3000 lux)
Number of subjects: 28
Study 12932084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bright light (> 3000 lux, 0.5 h on, 0.5 h off)
Number of subjects: 28
Study 12932084 — intervention group
Group type: COMPARATOR
Intervention: Ordinary dim indoor light (< 60 lux)
Number of subjects: 28
Study 10886051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedotozine (30 mg, t.d.s.)
Number of subjects: 29
Study 10886051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9250101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 127
Study 9250101 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation
Number of subjects: 127
Study 9250101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 127
Study 9250101 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study 7508322 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 725
Study 7508322 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid pattern photocoagulation
Number of subjects: 725
Study 7508322 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 725
Study 7508322 — intervention group
Group type: COMPARATOR
Intervention: Natural history groups
Number of subjects: 725
Study 3707799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plain
Number of subjects: 50
Study 3707799 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 50
Study 30001944 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 μg of salbutamol
Number of subjects: 30
Study 30001944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30001944 — intervention group
Group type: EXPERIMENTAL
Intervention: VSD group
Number of subjects: 30
Study 30001944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28557652 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LE)
Number of subjects: 240
Study 28557652 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC)
Number of subjects: 240
Study 28557652 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) + Metformin (MET)
Number of subjects: 240
Study 28557652 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (LE) + Metformin (MET)
Number of subjects: 240
Study 26013112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 'moving words' concept (1 English lesson relocated to sports hall for 1 year)
Number of subjects: 39
Study 26013112 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - regular physical education (3 hours per week)
Number of subjects: 39
Study 26013112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - English marks
Number of subjects: 39
Study 26013112 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - sports marks
Number of subjects: 39
Study 23893190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy (SLIT) for three years
Number of subjects: 140
Study 23893190 — intervention group
Group type: COMPARATOR
Intervention: Control group (never treated with specific immunotherapy, only symptomatic drugs)
Number of subjects: 140
Study 21866715 — intervention group
Group type: EXPERIMENTAL
Intervention: Music video exposure
Number of subjects: 51
Study 21866715 — intervention group
Group type: COMPARATOR
Intervention: Audio-only exposure
Number of subjects: 51
Study 18371963 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin 100 mg twice daily
Number of subjects: 1211
Study 18371963 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin 100 mg three times daily
Number of subjects: 1211
Study 18371963 — intervention group
Group type: COMPARATOR
Intervention: P(4) 90 mg 8% gel daily
Number of subjects: 1211
Study 17079850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (etidoronate, alendronate, risedronate)
Number of subjects: 0
Study 15533587 — intervention group
Group type: EXPERIMENTAL
Intervention: IDet + IAsp
Number of subjects: 395
Study 15533587 — intervention group
Group type: COMPARATOR
Intervention: NPH + HSI
Number of subjects: 395
Study 11151744 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg orally twice daily for 3 days)
Number of subjects: 10
Study 11151744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo orally twice daily for 3 days)
Number of subjects: 10
Study 11151744 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (10-500 microM in vitro)
Number of subjects: 10
Study 11151744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in vitro)
Number of subjects: 10
Study 10166598 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs identified in nursing journals
Number of subjects: 522
Study 10166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of effectiveness
Number of subjects: 522
Study 10166598 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity of Medline searches
Number of subjects: 522
Study 8314160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin, 30 mg/m2 (P-E)
Number of subjects: 243
Study 8314160 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin, 6 mg/m2 (P-I)
Number of subjects: 243
Study 3717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 109
Study 3717931 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 109
Study 3717931 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin with tobramycin
Number of subjects: 109
Study 29661523 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-Psychological intervention (PI)
Number of subjects: 0
Study 29661523 — intervention group
Group type: COMPARATOR
Intervention: Placebo-condition
Number of subjects: 0
Study 26921360 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin 3 mg/m2
Number of subjects: 788
Study 26921360 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin 6 mg/m2
Number of subjects: 788
Study 24372521 — intervention group
Group type: EXPERIMENTAL
Intervention: Yamamoto new scalp acupuncture (YNSA)
Number of subjects: 80
Study 24372521 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 80
Study 22203366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of GABA
Number of subjects: 63
Study 22203366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 63